Sweden
· Delayed Price · Currency is SEK · Price in DKK Curasight Company Description
Curasight A/S develops therapeutic and diagnostic solutions for the treatment of cancer.
It develops uTREAT therapeutic solutions, which are in the pre-clinical stage to treat glioblastoma (brain cancer), as well as have completed the pre-clinical stage for the treatment of non-small cell lung cancers, neuroendocrine neoplasms, head and neck cancer, and pancreatic cancers.
The company also develops uTRACE diagnostic solutions, which are in Phase II to treat prostate cancer, as well as have completed Phase II for the treatment of glioblastoma (brain cancer), prostate cancer, neuroendocrine neoplasms, head and neck cancer, non-small cell lung cancer, and urinary bladder cancer.
Curasight A/S was incorporated in 2013 and is based in Copenhagen, Denmark.
| Country | Denmark |
| Founded | 2013 |
| Industry | In Vitro and In Vivo Diagnostic Substances |
| Employees | 4 |
| CEO | Ulrich Krasilnikoff |
Contact Details
Address: Ole MaalOees Vej 3 Copenhagen, 2200 Denmark | |
| Phone | 45 22 83 01 60 |
| Website | curasight.com |
Stock Details
| Ticker Symbol | CURAS |
| Exchange | Nordic Growth Market |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Ulrich Krasilnikoff | Chief Executive Officer |
| Ulrich Krasilnikoff | Chief Financial Officer |
| Hanne Jensen | Chief Operating Officer |